Roth Capital and BTIG Initiate Coverage on HeartBeam and Connect Biopharma with Buy Ratings

Roth Capital starts coverage on HeartBeam (BEAT) with a $4 target, while BTIG initiates on Connect Biopharma (CNTB) with a $10 target. Both firms see strong growth potential in innovative healthcare technologies.